ontamalimab 
GtoPdb Ligand ID: 9340
|
Synonyms: PF-00547659 | PF-547659 | SHP647
Compound class:
Antibody
Comment: Ontamalimab (PF-00547659) is a fully human, IgG2, investigational monoclonal antibody targeting mucosal addressin cell adhesion molecule 1 (MADCAM1) [1-2]. It is being evaluated for clinical potential in inflammatory bowel diseases. PF-00547659 was granted FDA orphan drug designation for ulcerative colitis in November 2017.
|
| No information available. |
Summary of Clinical Use  |
| PF-00547659 has completed Phase 2 clinical trials for ulcerative colitis and Crohn's disease. Results from Phase 2 ulcerative colitis trial NCT01620255 were published by Vermeire et al. in 2017 [3] |
| Mechanism Of Action and Pharmacodynamic Effects |
| Lymphocyte homing to specialized lymphoid tissue and mucosal sites of the gastrointestinal tract is determined by the endothelial expression of MAdCAM-1, via interaction with integrin α4β7. The α4β7/MAdCAM-1 interaction is gut-specific. In experimental colitis models blockade of α4β7/MAdCAM-1 interaction reduces lymphocyte recruitment, mucosal damage and clinical signs of disease. PF-00547659 binds human MAdCAM-1 and is expected to act by the same molecular mechanism. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01620255 | A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis | Phase 2 Interventional | Shire | 3 | |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License